Artelo Biosciences, Inc.

NasdaqCM:ARTL Stock Report

Market Cap: US$3.1m

Artelo Biosciences Future Growth

Future criteria checks 0/6

Artelo Biosciences is forecast to grow earnings and revenue by 4.5% and 95.7% per annum respectively while EPS is expected to grow by 54.9% per annum.

Key information

4.5%

Earnings growth rate

54.9%

EPS growth rate

Pharmaceuticals earnings growth24.0%
Revenue growth rate95.7%
Future return on equityn/a
Analyst coverage

Low

Last updated24 Dec 2024

Recent future growth updates

Recent updates

Artelo jumps 21% as publication highlights pre-clinical data on drug platform

Aug 16

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Mar 28
Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Artelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy

Mar 09

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Nov 02
Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Relief For Cancer Patients In Artelo Bioscience Pipeline

Jul 12

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

May 20
Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Feb 04
Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

INO, VXRT, BTU and TTM among premarket gainers

Feb 02

Artelo Biosciences EPS misses by $0.04

Jan 14

Artelo Biosciences on go with cancer appetite recovery study

Nov 16

Earnings and Revenue Growth Forecasts

NasdaqCM:ARTL - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-17-18-183
12/31/2025N/A-11-10-104
12/31/2024N/A-8-17-174
9/30/2024N/A-9-8-8N/A
6/30/2024N/A-10-9-9N/A
3/31/2024N/A-10-9-9N/A
12/31/2023N/A-9-8-8N/A
9/30/2023N/A-10-8-8N/A
6/30/2023N/A-9-8-8N/A
3/31/2023N/A-10-8-8N/A
12/31/2022N/A-10-8-8N/A
9/30/2022N/A-13-9-9N/A
6/30/2022N/A-13-9-9N/A
3/31/2022N/A-12-8-8N/A
12/31/2021N/A-12-8-8N/A
11/30/2021N/A-9-7-7N/A
8/31/2021N/A-7-6-6N/A
5/31/2021N/A-7-5-5N/A
2/28/2021N/A-5-5-5N/A
11/30/2020N/A-5-5-5N/A
8/31/2020N/A-5-4-4N/A
5/31/2020N/A-4-6-5N/A
2/29/2020N/A-4-6-4N/A
11/30/2019N/A-3-5-3N/A
8/31/2019N/A-2-4-3N/A
5/31/2019N/A-2-2-2N/A
2/28/2019N/A-2-2-2N/A
11/30/2018N/A-3-2-2N/A
8/31/2018N/A-2N/A-2N/A
5/31/2018N/A-2N/A-1N/A
2/28/2018N/A-1N/A-1N/A
11/30/2017N/A-1N/A0N/A
8/31/2017N/A0N/A0N/A
5/31/2017N/A0N/A0N/A
2/28/2017N/A0N/A0N/A
11/30/2016N/A0N/A0N/A
8/31/2016N/A0N/A0N/A
5/31/2016N/A0N/A0N/A
2/29/2016N/A0N/A0N/A
11/30/2015N/A0N/A0N/A
8/31/2015N/A0N/A0N/A
5/31/2015N/A0N/A0N/A
2/28/2015N/A0N/A0N/A
11/30/2014N/A0N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARTL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ARTL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ARTL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ARTL is forecast to have no revenue next year.

High Growth Revenue: ARTL is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ARTL's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 20:14
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Artelo Biosciences, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertD. Boral Capital LLC.
Vernon BernardinoH.C. Wainwright & Co.
Matthew KaplanLadenburg Thalmann & Company